Women Infertility - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Women Infertility - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2014', provides an overview of the Women Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Women Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Women Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Women Infertility Overview 10
Therapeutics Development 11
Pipeline Products for Women Infertility - Overview 11
Pipeline Products for Women Infertility - Comparative Analysis 12
Women Infertility - Therapeutics under Development by Companies 13
Women Infertility - Therapeutics under Investigation by Universities/Institutes 16
Women Infertility - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Women Infertility - Products under Development by Companies 21
Women Infertility - Products under Investigation by Universities/Institutes 22
Women Infertility - Companies Involved in Therapeutics Development 23
Actavis plc 23
Merck & Co., Inc. 24
Reliance Life Sciences Pvt. Ltd. 25
ASKA Pharmaceutical Co., Ltd. 26
Teva Pharmaceutical Industries Limited 27
Zydus Cadila Healthcare Limited 28
Ferring International Center S.A. 29
Pantec Biosolutions AG 30
Access Pharmaceuticals, Inc. 31
Glycotope GmbH 32
PharmaEssentia Corporation 33
PregLem SA 34
Trophogen, Inc. 35
Isifer AB 36
Nora Therapeutics, Inc. 37
Hanmi Pharmaceuticals, Co. Ltd. 38
Finox AG 39
AlphaMab Co., Ltd 40
Dong-A Socio Group 41
Women Infertility - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
corifollitropin alfa - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DR-2011 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
choriogonadotropin alfa biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RTPR-013 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
follitropin alfa biosimilar - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
follitropin alfa biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
follitropin delta - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
barusiban - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Isifera - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FSH-GEX - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
menotropins - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
kisspeptin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NT-100 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
triptorelin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Progesterone Vaginal Gel Second Generation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
AKP-501 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PGL-1001 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Oral Fertility Drugs - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
HM-12160B - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TR-4401 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Luteinizing Hormone Analog - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
KN-015 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
follitropin alfa biosimilar - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
choriogonadotropin alfa biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Female Infertility - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Agonize FSHR for Infertility - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
FE-999310 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PEG-FSH - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Biosimilar 6 for Infertility - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Biosimilar 5 for Infertility - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Biosimilar 7 for Infertility and Oncology - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PGL-3001 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Women Infertility - Recent Pipeline Updates 88
Women Infertility - Dormant Projects 94
Women Infertility - Discontinued Products 95
Women Infertility - Product Development Milestones 96
Featured News & Press Releases 96
Jul 01, 2014: Finox Biotech and Save the Children Switzerland announce CHF 0.12 (€ 0.10) will be donated for every Bemfola product leaving the Swiss factory. 96
Jun 26, 2014: Nora Therapeutics Announces Initiation of Phase 2 RESPONSE Research Study 96
Mar 28, 2014: European Commission Grants Marketing Authorisation for Finox Biotech's bemfola for Treatment of Infertility 97
Jan 24, 2014: FINOX Biotech's Bemfola Receives CHMP Positive Opinion 97
Dec 17, 2013: Finox Biotech Announces First Patients Enrolled in Pivotal US Phase III study for rFSH 98
Nov 20, 2013: Glycotope's Fully Human and Glycooptimized Recombinant FSH-GEX Showed Superior Activity and Excellent Tolerability in a Phase II Clinical Trial for In Vitro Fertilisation 99
Oct 18, 2013: Merck Serono Announces US FDA Approval for Fertility Pen 100
Oct 17, 2013: EMD Serono Receives FDA Approval for Redesigned Fertility Pen 100
Sep 26, 2013: Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization Failures 103
Sep 09, 2013: Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Women Infertility, H2 2014 11
Number of Products under Development for Women Infertility - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Women Infertility - Pipeline by Actavis plc, H2 2014 23
Women Infertility - Pipeline by Merck & Co., Inc., H2 2014 24
Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 25
Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2014 26
Women Infertility - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 27
Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 28
Women Infertility - Pipeline by Ferring International Center S.A., H2 2014 29
Women Infertility - Pipeline by Pantec Biosolutions AG, H2 2014 30
Women Infertility - Pipeline by Access Pharmaceuticals, Inc., H2 2014 31
Women Infertility - Pipeline by Glycotope GmbH, H2 2014 32
Women Infertility - Pipeline by PharmaEssentia Corporation, H2 2014 33
Women Infertility - Pipeline by PregLem SA, H2 2014 34
Women Infertility - Pipeline by Trophogen, Inc., H2 2014 35
Women Infertility - Pipeline by Isifer AB, H2 2014 36
Women Infertility - Pipeline by Nora Therapeutics, Inc., H2 2014 37
Women Infertility - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 38
Women Infertility - Pipeline by Finox AG, H2 2014 39
Women Infertility - Pipeline by AlphaMab Co., Ltd, H2 2014 40
Women Infertility - Pipeline by Dong-A Socio Group, H2 2014 41
Assessment by Monotherapy Products, H2 2014 42
Number of Products by Stage and Target, H2 2014 44
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Women Infertility Therapeutics - Recent Pipeline Updates, H2 2014 88
Women Infertility - Dormant Projects, H2 2014 94
Women Infertility - Discontinued Products, H2 2014 95